BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows
reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural
similarities with mitoxantrone as well as general similarities with anthracyclines (such as
the tricyclic central quinoid chromophore).